Do FHIT gene alterations play a role in human solid tumors?

Area of Science:

• Genetics and Molecular Biology
• Cancer Research
• Genomic Instability

Background:

• The fragile histidine triad (FHIT) gene is located at a common fragile site (FRA3B) and is implicated in genomic instability, apoptosis, and DNA damage.
• FHIT gene alterations are frequently observed in various human cancers, but its precise role in tumor biology remains debated.
• Evidence suggests FHIT functions as a tumor suppressor, with reduced expression linked to adverse prognostic factors.

Purpose of the Study:

• To review and clarify the involvement of the FHIT gene in the processes of carcinogenesis and tumor progression.
• To elucidate the relationship between FHIT gene alterations and clinical outcomes in common solid malignancies.
• To consolidate current understanding of FHIT's role in breast, lung, cervical, esophageal, gastric, and colorectal cancers.

Main Methods:

• Literature review synthesizing existing research on the FHIT gene.
• Analysis of studies investigating FHIT alterations (mutations, epigenetic changes, LOH) and their correlation with cancer.
• Examination of FHIT protein expression levels in relation to tumor progression and patient survival.

Main Results:

• Loss or decreased expression of the Fhit protein is associated with tumor progression and poorer survival rates.
• Gene mutations, epigenetic alterations, and loss of heterozygosity are primary mechanisms driving FHIT expression changes.
• FHIT gene involvement in carcinogenesis and its impact on clinical outcomes are evident across multiple solid tumor types.

Conclusions:

• The FHIT gene plays a significant role in suppressing tumor development and progression.
• Alterations in FHIT expression are critical biomarkers for predicting clinical outcomes in solid tumors.
• Further research into FHIT's tumor-suppressive functions could yield novel therapeutic strategies for cancer treatment.